Heart Test Laboratories, Inc. (HSCS) Key Metrics
HSCS valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $14.6M
- Enterprise value
- $25.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 70.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.77
HSCS key metrics, FY2020–FY2026
Fiscal year ended April 30, 2026 · U.S. dollarsHSCS returns How much profit the business earns on the capital it uses.
HSCS financial health Debt, liquidity and how easily interest is covered.
HSCS efficiency & capital use Working capital cycle and where the cash goes.
HSCS valuation history
HSCS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
HSCS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
HSCS price vs earnings per share
HSCS key metrics
FY2020–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $5.1M | — | — | — | — | — | — |
| Enterprise value | $2.28B | — | — | — | — | — | — |
| Price / book | 0.0 | — | — | — | — | — | — |
| Earnings yield | −178.6% | — | — | — | — | — | — |
| Free cash flow yield | −145.9% | — | — | — | — | — | — |
| Share price at fiscal year-end | $1.95 | $3.50 | $9.20 | $88.80 | — | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | — | — | — | — | — | — |
| Earnings per share | −$3.48 | — | — | — | — | — | — |
| Operating cash flow per share | −$2.83 | — | — | — | — | — | — |
| Free cash flow per share | −$2.85 | — | — | — | — | — | — |
| Cash per share | $631.07 | — | — | — | — | — | — |
| Book value per share | $85.90 | — | — | — | — | — | — |
| Tangible book value per share | −$817.71 | — | — | — | — | — | — |
| Capex per share | $0.02 | — | — | — | — | — | — |
| Debt per share | $1,499.43 | — | — | — | — | — | — |
| Shares outstanding | 2.6M | — | — | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −8.1% | −233.0% | −175.0% | — | — | — | — |
| Return on invested capital (ROIC) | −0.5% | −284.5% | −371.5% | — | — | −336.1% | −396.2% |
| Return on assets (ROA) | −0.3% | −127.7% | −103.3% | −236.4% | −240.4% | −126.3% | −194.9% |
| Return on tangible assets | −0.3% | −336.3% | −0.4% | −193.3% | −231.1% | −127.2% | −194.9% |
| Financial health | |||||||
| Total debt | $3.94B | $3.0M | $1.0M | $1.6M | $6.2M | $3.1M | $942,710 |
| Cash & short-term investments | $1.66B | $1.1M | $5.8M | $1.7M | $918,260 | $723,481 | $496,853 |
| Net debt | $2.28B | $1.9M | −$4.8M | −$94,597 | $5.2M | $2.4M | $445,857 |
| Debt / equity | 17.46 | 14.55 | 0.14 | 6.79 | — | — | 2.99 |
| Debt / assets | 0.75 | 0.71 | 0.11 | 0.48 | 2.95 | 1.60 | 0.48 |
| Current ratio | 0.53 | 0.59 | 4.20 | 1.47 | 0.56 | 1.47 | 1.35 |
| Quick ratio | 0.40 | 0.41 | 3.84 | 1.10 | 0.36 | 0.80 | 0.60 |
| Interest coverage | -11.2 | -16.7 | -17.8 | -25.1 | -12.7 | -19.4 | — |
| Working capital | −$2.28B | −$1.5M | $5.6M | $863,690 | −$1.5M | $524,282 | $396,103 |
| Invested capital | $2.51B | $2.1M | $2.5M | $135,960 | −$811,282 | $445,728 | $761,408 |
| Tangible asset value | −$2.15B | −$1.4M | $1.59B | $230,557 | −$6.1M | −$1.9M | $315,551 |
| Net current asset value | −$2.45B | −$1.8M | $5.2M | −$360,095 | −$6.2M | −$2.2M | −$102,496 |
| Graham net-net per share | −$1,162.47 | — | — | — | — | — | — |
| Capital allocation | |||||||
| Capex / revenue | 1,029.2% | 694.0% | 673.5% | 355.5% | 13.4% | 2.8% | 17.8% |
| Capex / depreciation | 0.34 | 0.24 | 1.32 | 0.14 | 0.07 | 0.02 | 0.18 |
| Stock-based compensation / revenue | 30,386.3% | 5,744.5% | 2,177.6% | 4,821.5% | 475.9% | 96.4% | 210.4% |
| R&D / revenue | 65,733,086.4% | 100,830.0% | 15,476.1% | 47,783.8% | 20,883.1% | 6,672.6% | 3,178.8% |
| SG&A / revenue | 230,053.3% | 91,239.9% | 18,493.2% | 70,960.2% | 11,927.6% | 3,416.0% | 2,797.8% |
| Efficiency | |||||||
| Days sales outstanding | 183.8 | 36,963.3 | 11,735.7 | 11,400.1 | 1,232.6 | 1,610.3 | 746.0 |
| Days of inventory on hand | 899,735.3 | 1,798.4 | 2,354.0 | 8,295.4 | 7,547.2 | 6,627.1 | 2,836.3 |
| Days payables outstanding | 436,851.8 | 1,077.9 | 1,946.6 | 8,145.7 | 5,458.3 | 2,862.9 | 1,187.4 |
| Cash conversion cycle (days) | 463,067.4 | 37,683.8 | 12,143.1 | 11,549.9 | 3,321.5 | 5,374.5 | 2,394.9 |
| Receivables turnover | 1.99 | 0.01 | 0.03 | 0.03 | 0.30 | 0.23 | 0.49 |
| Payables turnover | 0.00 | 0.34 | 0.19 | 0.04 | 0.07 | 0.13 | 0.31 |
| Inventory turnover | 0.00 | 0.20 | 0.16 | 0.04 | 0.05 | 0.06 | 0.13 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 |
| Average receivables | $2,175 | $440,521 | $598,036 | $160,851 | $48,536 | $112,962 | $131,174 |
| Average payables | $159.3M | $383,422 | $539,776 | $663,057 | $515,263 | $347,284 | $358,786 |
| Average inventory | $328.1M | $639,723 | $652,769 | $675,249 | $712,456 | $803,891 | $857,008 |
| Intangibles / total assets | 45.1% | 38.3% | −16,690.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from HSCS's annual financial statements (latest annual report filed June 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
HSCS valuation and financial ratios
Heart Test Laboratories earned a return on equity of −8.1% and a return on invested capital of −0.5% in fiscal 2026. It ended the year with $3.9 billion of debt and $1.7 billion in cash and short-term investments, net debt of $2.3 billion.
See the HSCS income statement, the HSCS chart for price history, or the HSCS stock overview for the latest quote and news.
HSCS key metrics FAQ
What is Heart Test Laboratories's return on equity?
Heart Test Laboratories's return on equity (ROE) was −8.1% in fiscal 2026: net income of -$9.1 million on average shareholders' equity of $112.9 million.
What is Heart Test Laboratories's ROIC?
Heart Test Laboratories's return on invested capital was −0.5% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Heart Test Laboratories have?
Heart Test Laboratories had total debt of $3.9 billion at the end of fiscal 2026, a debt-to-equity ratio of 17.46.
What is Heart Test Laboratories's free cash flow yield?
Heart Test Laboratories generated -$7.5 million of free cash flow in fiscal 2026, a free cash flow yield of −145.9% on its market value at year-end ($5.1 million).
What is Heart Test Laboratories's current ratio?
Heart Test Laboratories's current ratio was 0.53 at the end of fiscal 2026: current assets were 0.53 times current liabilities.